212 related articles for article (PubMed ID: 18537155)
1. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.
Sugawara W; Haruta M; Sasaki F; Watanabe N; Tsunematsu Y; Kikuta A; Kaneko Y
Pediatr Blood Cancer; 2007 Sep; 49(3):240-9. PubMed ID: 16937357
[TBL] [Abstract][Full Text] [Related]
3. RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.
Honda S; Miyagi H; Suzuki H; Minato M; Haruta M; Kaneko Y; Hatanaka KC; Hiyama E; Kamijo T; Okada T; Taketomi A
Pediatr Surg Int; 2013 Nov; 29(11):1147-52. PubMed ID: 23989600
[TBL] [Abstract][Full Text] [Related]
4. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
6. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
8. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
9. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma.
Sakamoto LH; DE Camargo B; Cajaiba M; Soares FA; Vettore AL
Pediatr Res; 2010 Apr; 67(4):387-93. PubMed ID: 20032811
[TBL] [Abstract][Full Text] [Related]
10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U
Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215
[TBL] [Abstract][Full Text] [Related]
12. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
13. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.
Zhang HY; Rumilla KM; Jin L; Nakamura N; Stilling GA; Ruebel KH; Hobday TJ; Erlichman C; Erickson LA; Lloyd RV
Endocrine; 2006 Dec; 30(3):299-306. PubMed ID: 17526942
[TBL] [Abstract][Full Text] [Related]
14. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
[TBL] [Abstract][Full Text] [Related]
15. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
Lee SM; Lee WK; Kim DS; Park JY
Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
18. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
19. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
Chang Q; Ng HK
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
[TBL] [Abstract][Full Text] [Related]
20. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]